Delivery Order SPE2DR25D2100-SPE2DR26FA0EZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,304.98 to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 mL vials on November 14, 2025, with completion scheduled for November 17, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order totaling $19,186.58 to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 ml vials on September 8, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The contract involves no set-aside designation, indicating open competition among...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $15,003.41 firm fixed-price delivery order on August 5, 2025, for the supply of Injectafer 750 mg/15 mL vials. The contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million through December 2026. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Injectafer 750 mg/15 ml vials with a ceiling value of $13,079.20. This competitively awarded, firm fixed-price contract is classified as a child order and represents a non-set-aside procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order has an ultimate completion date of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,075.62 to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 mL vials on August 6, 2025, with an ultimate completion date of August 7, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. Injectafer is an intravenous iron replacement therapy used in the treatment of iron...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 1, 2025, for the supply of Injectafer 750 mg/15 ml vials. This is a firm fixed price delivery order with a ceiling value of $27,463.25 and an ultimate completion date of September 2, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and was awarded without a set-aside designation, indicating competitive procurement. This...
- The Defense Logistics Agency awarded a $19,061.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Injectafer 750 mg/15 mL vials. This non-set-aside contract, with a completion date of August 26, 2025, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical prime vendor vehicle with DLA, reflecting the agency's...
- The Defense Logistics Agency awarded a delivery order valued at $14,143.49 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Injectafer 750 mg/15 mL vials. This firm fixed-price, non-set-aside contract is scheduled for completion by June 3, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order valued at $13,203.17 from the Defense Logistics Agency (DLA) on November 17, 2025, for the supply of Injectafer 750 mg/15 ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 18, 2025, indicating a rapid fulfillment requirement. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,270.54 to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 ml vials. The contract, which is not set-aside, was competitively awarded on August 7, 2025, with an ultimate completion date of August 8, 2025. The product will be delivered to Conshohocken, Pennsylvania, utilizing a firm fixed price arrangement. This delivery order operates as a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D2100Indefinite Delivery Contract
- SPE2DR25D2100-SPE2DR26FA0EZDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Injectafer 750 mg/15 mL vials with a ceiling value of $12,323.51. The contract is non-competitive, firm fixed price delivery order awarded on November 20, 2025, with an ultimate completion date of November 21, 2025. Performance will be executed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company has demonstrated extensive capability in fulfilling federal medical supply needs through its portfolio of competitively awarded contracts with DLA and other government healthcare systems, including the Defense Health Agency and U.S. Coast Guard. Injectafer (ferric carboxymaltose) is an intravenous iron replacement therapy product, and this delivery order contributes to the company's ongoing support of pharmaceutical requirements across the federal healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.3k | 11/20/25 |